Beta-Klotho Protein Expression in Healthy Human Tissues and Liver Biopsies From Patients With MASLD or MASH

Background and Aims: Biologics based on the structure of fibroblast growth factor (FGF) 19 and 21 show strong beneficial effects in the treatment of metabolic dysfunction–associated steatotic liver disease (MASLD), including compensated cirrhosis. Studies in rodents indicated that the effectiveness...

Descripció completa

Dades bibliogràfiques

Autors principals:	Alexandra S. Aaldijk, Dicky Struik, Stan Driessen, Cristy R.C. Verzijl, Joanne Verheij, Max Nieuwdorp, Roos Eilers, Justina C. Wolters, Adriaan G. Holleboom, Johan W. Jonker
Format:	Artigo
Idioma:	Inglês
Publicat:	Elsevier 2025-01-01
Col·lecció:	Gastro Hep Advances
Matèries:	FGF19 FGF21 MASLD Hepatic Steatosis Inflammation
Accés en línia:	http://www.sciencedirect.com/science/article/pii/S2772572325001323
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!